Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1991 Jun;87(6):1916–1924. doi: 10.1172/JCI115217

Inhibition of immune functions by antiviral drugs.

W Heagy 1, C Crumpacker 1, P A Lopez 1, R W Finberg 1
PMCID: PMC296943  PMID: 1904068

Abstract

Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the antiviral agents, 3'-azido-3'-deoxythymidine (AZT), ribavirin, ganciclovir, 2'3'-dideoxyinosine (ddI), or acyclovir. To identify methods for assessing the effects of antiviral drugs on immune cells, the PBMC response to mitogens, Con A, or phytohemagglutinin was evaluated from measurements of [3H]thymidine and [14C]-leucine incorporation, cell growth, cellular RNA, DNA, and protein levels, and the PBMC proliferative cycle (i.e., progression from G0----G1----S----G2 + M). At clinically relevant concentrations, AZT, ribavirin, or ganciclovir diminished PBMC responsiveness to mitogen. The numbers of proliferating cells in G1, S, and G2 + M phases of the cell cycle, DNA content, and [3H]thymidine uptake were decreased in cultures treated with AZT, ribavirin, or ganciclovir. AZT or ribavirin but not ganciclovir reduced RNA and protein in the cultures and inhibited cell growth. Whereas AZT, ribavirin, or ganciclovir were antiproliferative, ddI or acyclovir had little, if any, effect on PBMC mitogenesis. The inhibitory effects of antivirals on immune cells may contribute to the immune deterioration observed in patients following prolonged use of the drugs.

Full text

PDF
1916

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Balzarini J., Pauwels R., Baba M., Herdewijn P., de Clercq E., Broder S., Johns D. G. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 1988 Mar 1;37(5):897–903. doi: 10.1016/0006-2952(88)90178-5. [DOI] [PubMed] [Google Scholar]
  3. Bhalla K., Birkhofer M., Li G. R., Grant S., MacLaughlin W., Cole J., Graham G., Volsky D. J. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood. 1989 Nov 1;74(6):1923–1928. [PubMed] [Google Scholar]
  4. Bowden R. A., Digel J., Reed E. C., Meyers J. D. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis. 1987 Dec;156(6):899–903. doi: 10.1093/infdis/156.6.899. [DOI] [PubMed] [Google Scholar]
  5. Browne M. J. Mechanism and specificity of action of ribavirin. Antimicrob Agents Chemother. 1979 Jun;15(6):747–753. doi: 10.1128/aac.15.6.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Buimovici-Klein E., Lange M., Ramey W. G., Grieco M. H., Cooper L. Z. Cell-mediated immune responses in AIDS. N Engl J Med. 1984 Aug 2;311(5):328–329. doi: 10.1056/NEJM198408023110512. [DOI] [PubMed] [Google Scholar]
  7. Collier A. C., Bozzette S., Coombs R. W., Causey D. M., Schoenfeld D. A., Spector S. A., Pettinelli C. B., Davies G., Richman D. D., Leedom J. M. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med. 1990 Oct 11;323(15):1015–1021. doi: 10.1056/NEJM199010113231502. [DOI] [PubMed] [Google Scholar]
  8. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  9. Crissman H. A., Steinkamp J. A. Rapid, one step staining procedures for analysis of cellular DNA and protein by single and dual laser flow cytometry. Cytometry. 1982 Sep;3(2):84–90. doi: 10.1002/cyto.990030204. [DOI] [PubMed] [Google Scholar]
  10. Crumpacker C., Heagy W., Bubley G., Monroe J. E., Finberg R., Hussey S., Schnipper L., Lucey D., Lee T. H., McLane M. F. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Ann Intern Med. 1987 Nov;107(5):664–674. doi: 10.7326/0003-4819-107-5-664. [DOI] [PubMed] [Google Scholar]
  11. Dainiak N., Worthington M., Riordan M. A., Kreczko S., Goldman L. 3'-Azido-3'-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br J Haematol. 1988 Jul;69(3):299–304. doi: 10.1111/j.1365-2141.1988.tb02366.x. [DOI] [PubMed] [Google Scholar]
  12. Darzynkiewicz Z., Evenson D., Staiano-Coico L., Sharpless T., Melamed M. R. Relationship between RNA content and progression of lymphocytes through S phase of cell cycle. Proc Natl Acad Sci U S A. 1979 Jan;76(1):358–362. doi: 10.1073/pnas.76.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dorsky D. I., Crumpacker C. S. Drugs five years later: acyclovir. Ann Intern Med. 1987 Dec;107(6):859–874. doi: 10.7326/0003-4819-107-6-859. [DOI] [PubMed] [Google Scholar]
  14. Drach J. C., Thomas M. A., Barnett J. W., Smith S. H., Shipman C., Jr Tritiated thymidine incorporation does not measure DNA synthesis in ribavirin-treated human cells. Science. 1981 May 1;212(4494):549–551. doi: 10.1126/science.7209549. [DOI] [PubMed] [Google Scholar]
  15. Edelson P. J. Clinical studies with ribavirin. Pediatr Infect Dis J. 1990 Sep;9(9 Suppl):S71–S73. [PubMed] [Google Scholar]
  16. Fauci A. S. ddI--a good start, but still phase I. N Engl J Med. 1990 May 10;322(19):1386–1388. doi: 10.1056/NEJM199005103221909. [DOI] [PubMed] [Google Scholar]
  17. Finberg R., Hom R. The role of T cell immunity in infection with the herpes group viruses. Year Immunol. 1986;2:267–278. [PubMed] [Google Scholar]
  18. Fischl M. A., Parker C. B., Pettinelli C., Wulfsohn M., Hirsch M. S., Collier A. C., Antoniskis D., Ho M., Richman D. D., Fuchs E. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990 Oct 11;323(15):1009–1014. doi: 10.1056/NEJM199010113231501. [DOI] [PubMed] [Google Scholar]
  19. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Henderly D. E., Freeman W. R., Causey D. M., Rao N. A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987 Apr;94(4):425–434. doi: 10.1016/s0161-6420(87)33454-2. [DOI] [PubMed] [Google Scholar]
  21. Johnson M., Caiazzo T., Molina J. M., Donahue R., Groopman J. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol. 1988 Oct;70(2):137–141. doi: 10.1111/j.1365-2141.1988.tb02454.x. [DOI] [PubMed] [Google Scholar]
  22. Knight V., McClung H. W., Wilson S. Z., Waters B. K., Quarles J. M., Cameron R. W., Greggs S. E., Zerwas J. M., Couch R. B. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981 Oct 31;2(8253):945–949. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  23. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  24. Levin M. J., Leary P. L., Arbeit R. D. Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1980 Jun;17(6):947–953. doi: 10.1128/aac.17.6.947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ljungman P., Lönnqvist B., Gahrton G., Ringdén O., Wahren B. Cytomegalovirus-specific lymphocyte proliferation and in vitro cytomegalovirus IgG synthesis for diagnosis of cytomegalovirus infections after bone marrow transplantation. Blood. 1986 Jul;68(1):108–112. [PubMed] [Google Scholar]
  26. McCormick J. B., King I. J., Webb P. A., Scribner C. L., Craven R. B., Johnson K. M., Elliott L. H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986 Jan 2;314(1):20–26. doi: 10.1056/NEJM198601023140104. [DOI] [PubMed] [Google Scholar]
  27. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mitsuya H., Jarrett R. F., Matsukura M., Di Marzo Veronese F., DeVico A. L., Sarngadharan M. G., Johns D. G., Reitz M. S., Broder S. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2033–2037. doi: 10.1073/pnas.84.7.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Molina J. M., Groopman J. E. Bone marrow toxicity of dideoxyinosine. N Engl J Med. 1989 Nov 23;321(21):1478–1478. doi: 10.1056/NEJM198911233212113. [DOI] [PubMed] [Google Scholar]
  30. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  31. Roberts R. B., Hollinger F. B., Parks W. P., Rasheed S., Laurence J., Heseltine P. N., Makuch R. W., Lubina J. A., Johnson K. M. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group. AIDS. 1990 Jan;4(1):67–72. doi: 10.1097/00002030-199001000-00009. [DOI] [PubMed] [Google Scholar]
  32. Roberts R. B., Jurica K., Meyer W. A., 3rd, Paxton H., Makuch R. W. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients. J Infect Dis. 1990 Sep;162(3):638–642. doi: 10.1093/infdis/162.3.638. [DOI] [PubMed] [Google Scholar]
  33. Shapiro H. M. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry. 1981 Nov;2(3):143–150. doi: 10.1002/cyto.990020302. [DOI] [PubMed] [Google Scholar]
  34. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Whitley R. J., Blum M. R., Barton N., de Miranda P. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. Am J Med. 1982 Jul 20;73(1A):165–171. doi: 10.1016/0002-9343(82)90084-5. [DOI] [PubMed] [Google Scholar]
  36. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  37. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 1989 Jul 28;245(4916):412–415. doi: 10.1126/science.2502840. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES